VHL and renal cell carcinoma: For example, based on clinical trial data, patients with renal cell carcinoma who have Von Hippel-Lindau tumor suppressor (VHL) alterations may benefit from treatments like sunitinib, sorafenib, bevacizumab, or axitinib [35].